Ellen Strahlman, M.D., M.H.Sc., is the Executive Vice President for Research and Development and Chief Medical Officer for BD (Becton, Dickinson and Company). In this role, she oversees the Company’s Innovation System, Research & Development (R&D) and Medical Affairs functions. As an Officer of the Company, she is the MC Co-Chair of the Science, Marketing, Innovation and Technology Committee for the BD Board of Directors; and she serves as a member of the Company’s Management Committee (MC), Corporate Business Development Team, Corporate Ethics Steering Team, and the BD Leadership Team. In her Management capacity, Ellen Co-Chairs the company’s Innovation and New Product Development Council, Chairs the R&D and the Medical Affairs Leadership Teams and leads the Office of Science, Medicine & Technology for BD, comprising more than 3500 associates worldwide.
Dr. Strahlman joined BD in May 2013, from GlaxoSmithKline , having served as the Senior Vice President and Chief Medical Officer since 2008 in addition to working in the Office of the CEO as Senior Medical Advisor and Global Head of Neglected Tropical Diseases. As GSK’s Chief Medical Officer, Dr. Strahlman had accountability for medical safety and patient matters for all programs in development and commercialized products in the Vaccines, Pharmaceutical and Consumer businesses, as well as organizational responsibility for activities that included medical affairs, regulatory affairs, clinical safety and other areas. Prior to GlaxoSmithKline, Dr. Strahlman held executive leadership roles at Merck, Novartis, Pfizer, and Bausch & Lomb that included oversight of the development, licensing and commercialization of proprietary and generic pharmaceuticals, vaccines, drug delivery systems, consumer products and medical devices.
Throughout her career, Ellen has, and continues to be, a passionate advocate for the democratization of technology and access to high-quality healthcare and has worked to create business solutions designed to deliver medicines, products and services on a global basis. . She currently serves on the Board of Directors for Sycona Partners LLP, the Advisory Boards for the British Medical Journal and the Johns Hopkins Bloomberg School of Public Health, Health Advisory Board, and in November 2012, she became a Fellow of the Salzburg Global Seminars, a non-profit organization that holds seminars that strive to "challenge present and future leaders to solve issues of global concern. Past roles include serving on the Board of Directors for ViiV Healthcare plc, Industry Representative on the FDA/CDER Dermatologic & Ophthalmic Drug Advisory Committee, WHO Partnership for Disease Control Initiatives, UN Commission on Life-Saving Commodities for Women & Children and the Healthcare Coalition for the International Centre for Missing & Exploited Children.
Ellen is a graduate of Harvard University (Biochemical Sciences) and obtained her medical degree from the Johns Hopkins School of Medicine. She has medical qualifications in general surgery (Johns Hopkins) and ophthalmology (the Wilmer Institute, Johns Hopkins). Finally, Ellen earned her Masters Degree in Health Sciences from the Johns Hopkins Bloomberg School of Public Health as a Carnegie-Mellon Physician Public Health Fellow.